Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

12 Nov 2009 07:00

RNS Number : 3824C
Futura Medical PLC
12 November 2009
 



For immediate release 

12 November 2009

Futura Medical plc

("Futura" or "the Company")

Placing

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £1.46 million are being raised through the issue of 4,864,471 new ordinary shares of 0.2 pence each in Futura ("Ordinary Shares"), to new and existing institutional and other investors at a price of 30 pence per share The Placing represents approximately 7.8% of the Company's issued share capital.

The net proceeds of the fundraising will be used to provide additional working capital, to support the regulatory approval of CSD500, to progress the Company's developmental projects, as well as to evaluate some early stage research leads. Further it is expected a strengthened balance sheet will assist in the Company's out-licensing negotiations with pharmaceutical and other partners. 

The Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the Ordinary Shares will commence on AIM at 8:00am on 18 November 2009. 

Futura's total issued shared capital following the admission of the Ordinary Shares will be 67,483,311. The total number of voting rights in the Company will be 67,483,311.

James Barder, Futura's Chief Executive, said: "We are pleased with the support of new and existing investors in this Placing, which will allow us to progress our exciting pipeline of products and give us the ability to capture more of their long term value. We continue to manage our costs carefully and intend to exploit our low cost business model to progress those projects that we believe have significant upside. Having a strengthened balance sheet will undoubtedly be of assistance in our current out-licensing discussions."

For any further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.co.uk

www.futuramedical.co.uk 

Nomura Code Securities Limited 

Charles Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact: 

Buchanan Communications

Mark Court / Stasa Filiplic / Jennie Spivey

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEKFLFFKFBFFBQ
Date   Source Headline
6th May 20224:41 pmRNSSecond Price Monitoring Extn
6th May 20224:35 pmRNSPrice Monitoring Extension
26th Apr 20227:00 amRNSFull Year Results 2021
14th Apr 20223:54 pmRNSFutura Medical Notice of Preliminary Results 2021
11th Apr 20224:28 pmRNSTR-1: Notification of major holdings
1st Apr 20224:58 pmRNSTR-1: Notification of major holdings
23rd Mar 20227:00 amRNSFutura Announces Collaboration with Menarini
2nd Feb 20225:30 pmRNSTR-1:Notification of major holdings
13th Jan 202210:32 amRNSRemuneration of Non-Executive Directors and TVR
20th Dec 20217:00 amRNSUS regulatory and commercial update for MED3000
2nd Dec 202112:02 pmRNSTR-1: Notification of major holdings
30th Nov 20217:00 amRNSBlock Listing Six Monthly Return
30th Nov 20217:00 amRNSFutura Medical plc Total Voting Rights
28th Oct 20217:00 amRNSFutura Medical plc Board Appointment
8th Oct 20217:00 amRNSFutura Medical plc Board Appointment
5th Oct 20214:05 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSInterim Results for Six Months ended 30 June 2021
27th Sep 20217:00 amRNSFutura Announces Collaboration with Labatec Pharma
17th Sep 20217:00 amRNSNotice of Interim Results
15th Sep 20217:00 amRNSFirst Patient visit in MED3000 Confirmatory Study
8th Sep 20213:49 pmRNSTR1: Notification of Major Holdings
31st Aug 20217:00 amRNSFutura Medical Announces Collaboration of MED3000
19th Jul 20217:00 amRNSFDA regulatory and commercial update for MED3000
28th Jun 20211:26 pmRNSResult of AGM
28th Jun 20217:00 amRNSAGM Statement
25th Jun 20212:55 pmRNSTR1: Notification of Major Holdings
15th Jun 20213:48 pmRNSTR-1: Notification of major holdings
9th Jun 20213:58 pmRNSTR-1: Notification of major holdings
3rd Jun 20214:19 pmRNSTR-1: Notification of major holdings
3rd Jun 202111:00 amRNSNotice of AGM and Annual Report
2nd Jun 202112:50 pmRNSResult of General Meeting & Total Voting Rights
1st Jun 20217:00 amRNSBlock Listing Six Monthly Return
17th May 20213:08 pmRNSPosting of Circular and Notice of General Meeting
17th May 20217:00 amRNSResult of Placing and Retail Offer
14th May 20214:41 pmRNSSecond Price Monitoring Extn
14th May 20214:35 pmRNSPrice Monitoring Extension
14th May 20214:31 pmRNSRetail Offer by PrimaryBid
14th May 20214:30 pmRNSProposed Placing to raise £10 mil & Retail Offer
4th May 20215:18 pmRNSTR-1: Notification of major holdings
4th May 20215:15 pmRNSTR-1: Notification of major holdings
4th May 20217:00 amRNSTotal Voting Rights
30th Apr 20217:00 amRNSFutura Receives Approval from EU Notified Body
28th Apr 20212:57 pmRNSTR-1: Notification of major holdings
28th Apr 20219:31 amRNSTR-1: Notification of major holdings
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.